IMU-838 tablets

Phase 3

00%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Nov '26

IMUXPhase 3$134M

IMU-838 tablets Phase 3 Est. Readout (ENSURE-1)

IMU-838 tablets• Multiple Sclerosis, Relapsing-Remitting1,121

Nov 2026~Estimated

00%

Competitive Landscape

0 competitors in Multiple Sclerosis, Relapsing-Remitting

Drug Information

Target Indication

Multiple Sclerosis, Relapsing-Remitting

Clinical Trial

Last updated: 2/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

IMUX

IMMUNIC, INC.

Related Pipeline

Multiple Sclerosis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts